Nykode Therapeutics AS (OTCMKTS:VACBF) Short Interest Update

Nykode Therapeutics AS (OTCMKTS:VACBF) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 1,197,800 shares, a decrease of 45.5% from the January 15th total of 2,199,700 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Nykode Therapeutics AS Price Performance

OTCMKTS VACBF opened at $0.24 on Friday. Nykode Therapeutics AS has a 52-week low of $0.24 and a 52-week high of $0.95. The business has a 50 day simple moving average of $0.24 and a 200 day simple moving average of $0.50.

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10.